Partnership expands to develop new prescription digital therapeutic for schizophrenia

Boehringer Ingelheim and Click Therapeutics have announced the launch of an expanded collaboration for development and commercialization of a second prescription digital therapeutic for those diagnosed with schizophrenia.

According to a release from Boehringer, the collaboration intends to produce a novel mobile application that combines multiple clinically validated therapeutic interventions for use alone and in combination with pharmaceutical therapy to help people with schizophrenia achieve positive clinical outcomes.

“We are very excited to expand our collaboration with Click Therapeutics and further tap into their expertise in developing efficacious and engaging digital therapeutics,” Boehringer Ingelheim Corporate Vice President Nedim Pipic, MD, said in the release. “It opens new horizons on our journey toward advancing mental health care by combining pharmacotherapies with newly emerging digital technologies.”

The prescription digital therapeutic is expected to build on development and clinical successes with key patient insights from the companies’ current collaboration, CT-155, which has been in effect since September 2020, the release stated.

Boehringer additionally revealed in the release that Click Therapeutics will receive an upfront payment, funding for research and development activities as well as clinical, regulatory and commercial milestone payments up to a total of $460 million.

“Our collaboration with Boehringer Ingelheim offers significant potential to bring new digital treatment options to a currently underserved patient population,” Click Therapeutics CEO David Benshoof Klein said in the release. “Our teams share a passion to pursue new, groundbreaking approaches to treatment and a mission to make a difference for patients.”